Centessa Pharmaceuticals PLC 10-Q quarterly reports

Centessa Pharmaceuticals plc has entered into a definitive agreement to be acquired by Eli Lilly and Company for $38.00 per share in cash, plus a contingent value right.

Centessa Pharmaceuticals reported a widened net loss in Q3 2025 as increased R&D spending fueled progress in its OX2R agonist pipeline, including positive ORX750 and ORX142 clinical data.

Centessa Pharmaceuticals reported a reduced net loss and extended its cash runway into mid-2027, driven by strategic focus on its OX2R agonist program and a new licensing agreement with Genmab.

Centessa Pharmaceuticals announces its Q1 2025 financial results, highlighting a license agreement with Genmab and progress in its orexin agonist program.

Centessa Pharmaceuticals filed an amendment to its Q3 2024 report to include disclosures of Rule 10b5-1 trading plans adopted by certain officers.

Centessa Pharmaceuticals reports its third quarter 2024 results, highlighting a strategic shift to prioritize its Orexin program and discontinuing the SerpinPC program.

Centessa Pharmaceuticals has filed an amended 10-Q report to correct a typographical error in a previously submitted exhibit, with no changes to the financial or other information.

Centessa Pharmaceuticals reported its second quarter 2024 financial results, highlighting progress in its clinical programs and pipeline development.

Centessa Pharmaceuticals reports a net loss of $38 million for the first quarter of 2024, while highlighting progress in its clinical programs and financial position.